Watch this brief welcome message from David Meeker, MD, Chairman, President, and CEO of Rhythm Pharmaceuticals, Inc.
Unlike general obesity, rare genetic diseases of obesity are caused by an impactful variant in a gene, resulting in the dysfunction of key systems that regulate energy balance.1 The melanocortin-4 receptor (MC4R) pathway is one such key system.1,2 This dysfunction can lead to hyperphagia (also known as pathological, insatiable hunger) and early-onset, severe obesity, the hallmark symptoms of rare genetic diseases of obesity.1,3
Learn about Rhythm's latest publications and conference presentations, including a poster describing the study design of the phase 2 DAYBREAK trial, which will evaluate setmelanotide for weight loss and hunger reduction in patients with a genetic variant associated with the melanocortin-4 receptor (MC4R) pathway.
Connect With Rhythm Pharmaceuticals
- Huvenne H, et al. Obes Facts. 2016;9(3):158-173.
- da Fonseca ACP, et al. J Diabetes Complications. 2017;31(10):1549-1561.
- Heymsfield SB, et al. Obesity (Silver Spring). 2014;22(suppl 1):S1-S17.